TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31505127

Group type: EXPERIMENTAL
Intervention: Moderate-load resistance exercise (6 sets at 70% 1-repetition maximum, 90-s rest)
Number of subjects: 11

Group type: COMPARATOR
Intervention: High-load resistance exercise (6 sets at 90% 1-repetition maximum, 180-s rest)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Moderate-load resistance exercise
Number of subjects: 11

Group type: COMPARATOR
Intervention: High-load resistance exercise
Number of subjects: 11
Study: 29939912

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention for chronic disease management
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 302
Study: 28732741

Group type: EXPERIMENTAL
Intervention: Long-acting water-stable organosilane (WSO)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (inert saline solution)
Number of subjects: 18
Study: 26710954

Group type: EXPERIMENTAL
Intervention: 20 ml oral lactulose solution, twice a day for 4 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Defecation habits training, diet management, and drinking adequate water
Number of subjects: 200
Study: 24182675

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 422
Study: 21411114

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 18241718

Group type: EXPERIMENTAL
Intervention: Palatal implants
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 62
Study: 16483159

Group type: EXPERIMENTAL
Intervention: Varicocelectomy with hyperbaric oxygenation (HBO)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Solitary varicocelectomy
Number of subjects: 96
Study: 15096608

Group type: EXPERIMENTAL
Intervention: Low-level visual training
Number of subjects: 0
Study: 11137070

Group type: EXPERIMENTAL
Intervention: Filshie Clip
Number of subjects: 2126

Group type: COMPARATOR
Intervention: Hulka Clip
Number of subjects: 2126
Study: 9567903

Group type: EXPERIMENTAL
Intervention: Multimedia program
Number of subjects: 28

Group type: COMPARATOR
Intervention: Text-based information
Number of subjects: 28
Study: 8363468

Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplement
Number of subjects: 5380

Group type: EXPERIMENTAL
Intervention: Riboflavin/niacin
Number of subjects: 5380

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 5380

Group type: COMPARATOR
Intervention: Control group (not receiving vitamins)
Number of subjects: 5380
Study: 2872809

Group type: EXPERIMENTAL
Intervention: Terazosin (once daily)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Prazosin (twice daily)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 30907155

Group type: EXPERIMENTAL
Intervention: Three-dimensional Shoulder Pain Alignment mobilization protocol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 20
Study: 31290251

Group type: EXPERIMENTAL
Intervention: Low walkability areas
Number of subjects: 450

Group type: COMPARATOR
Intervention: High walkability areas
Number of subjects: 450
Study: 28176470

Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg (fasted) under unmodified gastric pH
Number of subjects: 26

Group type: COMPARATOR
Intervention: Gefitinib 250 mg (fasted) 1 hour after ranitidine 450 mg (elevated gastric pH)
Number of subjects: 26
Study: 25286883

Group type: EXPERIMENTAL
Intervention: Scissor kicks (SK)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rocking (RO)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Running (RU)
Number of subjects: 12
Study: 24479279

Group type: EXPERIMENTAL
Intervention: SureFil SDR flow (SDR)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Filtek Silorane (FS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: G‐aenial Flo bulk fill (GF)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: G‐aenial Universal Flo bulk fill (GUF)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GC Kalore bulk fill (GK)
Number of subjects: 50
Study: 20825806

Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo lubricant gel
Number of subjects: 62
Study: 19097870

Group type: EXPERIMENTAL
Intervention: Day hospital psychotherapy (DHP)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Outpatient individual psychotherapy (OIP)
Number of subjects: 114
Study: 16388507

Group type: EXPERIMENTAL
Intervention: Group-1 (PSA cut-off of 4.0 ng/ml and/or abnormal DRE/TRUS)
Number of subjects: 13901

Group type: COMPARATOR
Intervention: Group-2 (PSA cut-off of 3.0 ng/ml)
Number of subjects: 13901
Study: 15288876

Group type: EXPERIMENTAL
Intervention: Structured individualised transfer method
Number of subjects: 162

Group type: COMPARATOR
Intervention: Existing ad hoc transfer methods
Number of subjects: 162
Study: 11368132

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 135

Group type: COMPARATOR
Intervention: Adding myeloperoxidase (280 ng/ml) to neutrophil granulocyte suspensions
Number of subjects: 135
Study: 9412638

Group type: EXPERIMENTAL
Intervention: Human pial arteries under pressure (60 mm Hg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human pial arteries at 30 mm Hg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human pial arteries at 60 and 90 mm Hg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human pial arteries contracted to KCl 30 mmol/L, norepinephrine 1 μmol/L, and vasopressin 0.1 μmol/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human pial arteries relaxed to acetylcholine 3 μmol/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arterial distensibility at lower pressures (5 to 50 mm Hg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human omental arteries of comparable size
Number of subjects: 0
Study: 8501160

Group type: EXPERIMENTAL
Intervention: 10 mg MMI daily
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: 40 mg MMI daily
Number of subjects: 509

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 509
Study: 2820202

Group type: EXPERIMENTAL
Intervention: Fibre supplement (5 g/day in Study I, 7 g/day in Study II)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Fibre supplement
Number of subjects: 105
Study: 31005551

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Polypharmacy (≥6 drugs)
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Probable depression
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Older age, overweight, comorbidity, abnormal C-reactive protein
Number of subjects: 842
Study: 28129275

Group type: EXPERIMENTAL
Intervention: Flexible Daily Undulating Periodization (FDUP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Traditional Daily Undulating Periodization (DUP)
Number of subjects: 25
Study: 25832541

Group type: EXPERIMENTAL
Intervention: Fresh red onion meal (100 g providing 156.3 ± 3.4 μmol (47 mg) quercetin)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Quercetin dihydrate tablet (1800 ± 150 μmol (544 mg) of quercetin)
Number of subjects: 6
Study: 23834742

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over PMd
Number of subjects: 33

Group type: COMPARATOR
Intervention: 5 Hz rTMS over PMd
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no rTMS)
Number of subjects: 33
Study: 21501648

Group type: EXPERIMENTAL
Intervention: Experimental cigarettes with up to 60% glycerol containing tobacco-substitute sheet
Number of subjects: 0
Study: 19070989

Group type: EXPERIMENTAL
Intervention: Anger mood induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anxiety mood induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Happy mood induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 0
Study: 17692722

Group type: EXPERIMENTAL
Intervention: Valdecoxib 10 mg QD
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg BID
Number of subjects: 508

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: All groups (valdecoxib, naproxen, placebo)
Number of subjects: 508
Study: 15055856

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study: 12515634

Group type: EXPERIMENTAL
Intervention: FEC regimen (5‐Fu, epirubicin, cyclophosphamide)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ET regimen (epirubicin, paclitaxel)
Number of subjects: 48
Study: 9703125

Group type: EXPERIMENTAL
Intervention: Topical tretinoin
Number of subjects: 0
Study: 7972346

Group type: EXPERIMENTAL
Intervention: Valerian extract (Valdispert forte, 405 mg t.i.d.)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2789957

Group type: EXPERIMENTAL
Intervention: Counting
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Guidelines
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study: 1095248

Group type: EXPERIMENTAL
Intervention: Rifampicin plus ethambutol once a week (ER1)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Rifampicin plus ethambutol daily for 2 months and then once a week (ER7ER1)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Ethionamide plus pyrazinamide plus cycloserine daily for 6 months and then ethionamide plus pyrazinamide daily (EtZC)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Rifampicin plus ethambutol twice a week (ER2)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Rifampicin plus ethambutol daily (ER7)
Number of subjects: 575
Study: 31769402

Group type: EXPERIMENTAL
Intervention: PXVX0200 (1 × 10^9 CFU)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: PXVX0200
Number of subjects: 374
Study: 30247329

Group type: EXPERIMENTAL
Intervention: Elective sigmoidectomy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 109
Study: 29045169

Group type: EXPERIMENTAL
Intervention: Topical palmitoylethanolamide (PEA) (Defluxa)
Number of subjects: 15
Study: 25483019

Group type: EXPERIMENTAL
Intervention: Greater daily walking activity
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Low-intensity walking activity
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Total daily walking activity
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control brain region (thalamus)
Number of subjects: 92
Study: 23473435

Group type: EXPERIMENTAL
Intervention: Focus device
Number of subjects: 54
Study: 22074713

Group type: COMPARATOR
Intervention: clinical/CD4 monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: clinical/CD4/viral load monitoring
Number of subjects: 0
Study: 19420395

Group type: EXPERIMENTAL
Intervention: Self-regulation group
Number of subjects: 113

Group type: COMPARATOR
Intervention: Open group
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study: 17008337

Group type: EXPERIMENTAL
Intervention: Staff sexuality training programme (two-day workshop)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 74
Study: 15286181

Group type: EXPERIMENTAL
Intervention: Explicit Information (EI) provided to participants with basal ganglia stroke
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Explicit Information (No-EI) for participants with basal ganglia stroke
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit Information (EI) provided to healthy controls (HC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Explicit Information (No-EI) for healthy controls (HC)
Number of subjects: 0
Study: 10612768

Group type: EXPERIMENTAL
Intervention: Cefuroxime receipt 2 hours or more before incision
Number of subjects: 3028

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus with a preoperative blood glucose level of 200 mg/dL or more
Number of subjects: 3028

Group type: EXPERIMENTAL
Intervention: Staple use for skin closure
Number of subjects: 3028

Group type: COMPARATOR
Intervention: Study period (January 1995‐March 1998)
Number of subjects: 3028
Study: 9578541

Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs (AEDs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antiepileptic drugs (optimal doses)
Number of subjects: 0
Study: 8111800

Group type: EXPERIMENTAL
Intervention: Glyburide (1.25 or 2.5 mg/day)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Glipizide (2.5 or 5 mg/day)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Glyburide (mean dose 8.5 mg/day)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Glipizide (mean dose 15.4 mg/day)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Both glyburide and glipizide
Number of subjects: 145
Study: 3903062

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (cisplatin, doxorubicin, cyclophosphamide: PACe)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Chlorambucil (CB)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (PACe)
Number of subjects: 85
Study: 29343527

Group type: EXPERIMENTAL
Intervention: Chemotherapy for NF1-OPG
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Chemotherapy for sporadic OPG
Number of subjects: 155

Group type: COMPARATOR
Intervention: Comparison between NF1-OPG and sporadic OPG
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: VA improvement in NF1-OPG
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: VA improvement in sporadic OPG
Number of subjects: 155
Study: 27477797

Group type: EXPERIMENTAL
Intervention: 125 mg methylprednisolone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study: 25435713

Group type: EXPERIMENTAL
Intervention: Mental practice combined with physical practice for four weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Physical practice only
Number of subjects: 20
Study: 20816708

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 39
Study: 16275178

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose atorvastatin (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12523590

Group type: EXPERIMENTAL
Intervention: Water-perfused catheter
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rectosphincteric balloon probe
Number of subjects: 12
Study: 9665503

Group type: EXPERIMENTAL
Intervention: Indinavir 400 mg with delavirdine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Indinavir 600 mg with delavirdine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Indinavir 800 mg alone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Indinavir with delavirdine
Number of subjects: 14
Study: 7544368

Group type: EXPERIMENTAL
Intervention: FK 506 treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 2547409

Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pear shaped spacer attachment (PSS)
Number of subjects: 7
Study: 912951

Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin (HBIG) administered at five to eight week intervals.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no immunoglobulin).
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin (HBIG).
Number of subjects: 28
Study: 30225991

Group type: EXPERIMENTAL
Intervention: HLA-A*02
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: HLA-B*35
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: HLA-DRB1*07:01
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: HLA-DQB1*03:01
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: HLA-A*01/B*08/DRB1*03:01
Number of subjects: 641
Study: 27612943

Group type: EXPERIMENTAL
Intervention: Optimal Health Program (9 sessions: 8 + 1 booster session)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 166
Study: 25262270

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 12944

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12944
Study: 23543067

Group type: EXPERIMENTAL
Intervention: 30-min moderate (M) aerobic training
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 60-min moderate (M) aerobic training
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 30-min heavy (H) aerobic training
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 60-min heavy (H) aerobic training
Number of subjects: 15
Study: 19467804

Group type: EXPERIMENTAL
Intervention: Interactive teaching session focused on prostate and rectum MR anatomy compared with CT anatomy.
Number of subjects: 31

Group type: COMPARATOR
Intervention: 3D‐CRT planning without mention of prostate or rectal contouring.
Number of subjects: 31
Study: 19022811

Group type: EXPERIMENTAL
Intervention: High-dose immunosuppressive therapy and autologous stem cell transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 0
Study: 16855072

Group type: EXPERIMENTAL
Intervention: Sitagliptin 200 mg bid
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12500203

Group type: EXPERIMENTAL
Intervention: VPA-985 25 mg twice daily
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: VPA-985 125 mg twice daily
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: VPA-985 250 mg twice daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 10663216

Group type: EXPERIMENTAL
Intervention: Birth weight
Number of subjects: 1268
Study: 8792942

Group type: EXPERIMENTAL
Intervention: cloxacillin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: cephalexin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: erythromycin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: fusidic acid
Number of subjects: 20
Study: 1297231

Group type: EXPERIMENTAL
Intervention: Glutathione (GSH, 1200 mg, i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 0
Study: 6394127

Group type: EXPERIMENTAL
Intervention: Netilmicin-ticarcillin (NT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tobramycin-ticarcillin (TT)
Number of subjects: 60
Study: 31080947

Group type: EXPERIMENTAL
Intervention: Minimal-flow anaesthesia (MF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: High-flow anaesthesia (HF)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both MF and HF anaesthesia
Number of subjects: 80
Study: 29025005

Group type: EXPERIMENTAL
Intervention: Extended-release paracetamol (ER-APAP) 2 x 665 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: ER-APAP
Number of subjects: 25
Study: 27048210

Group type: COMPARATOR
Intervention: Vortioxetine (20 or 40 mg) with or without ethanol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vortioxetine (10 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ethanol
Number of subjects: 100
Study: 25293834

Group type: EXPERIMENTAL
Intervention: Haptotherapy treatment
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Internet psycho-education
Number of subjects: 3

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 3
Study: 22516039

Group type: EXPERIMENTAL
Intervention: Standard dosing regimen (15 mg MTX once a week)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Accelerated dosing regimen (25 mg MTX once a week)
Number of subjects: 19
Study: 19853680

Group type: EXPERIMENTAL
Intervention: RUTI (5-200 microg doses)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 17963623

Group type: EXPERIMENTAL
Intervention: Recombinant staphylokinase (r‐Sak)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Recombinant tissue-type plasminogen activator (rt‐PA)
Number of subjects: 210
Study: 16116012

Group type: EXPERIMENTAL
Intervention: Ketamine sedation (0.5 mg . kg(‐1) . h(‐1) continuous infusion after IV administration of 0.01 mg/kg midazolam)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo infusion (volume-equivalent)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketamine sedation
Number of subjects: 30
Study: 12324731

Group type: EXPERIMENTAL
Intervention: Total Vital Capacity Maneuvers (TVCM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no total vital capacity maneuver)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 24
Study: 10408158

Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA) therapy for 2 weeks before LH-RH analogue injection
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA) therapy for 4 weeks before LH-RH analogue injection
Number of subjects: 25

Group type: COMPARATOR
Intervention: LH-RH analogue injection
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CMA administration after LH-RH analogue application
Number of subjects: 25
Study: 7673760

Group type: EXPERIMENTAL
Intervention: Thallium-201 SPECT
Number of subjects: 170

Group type: COMPARATOR
Intervention: Conventional exercise test (ST-depression)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Combination of SPECT score >= 4 and/or ST-depression in >= 3 leads
Number of subjects: 170
Study: 2405132

Group type: EXPERIMENTAL
Intervention: Data coordination and management by the DDC of the GFRD Study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coordination and communication tasks in the multicenter study
Number of subjects: 0
Study: 6109465

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (0.4‐0.8 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Benzoctamine (10‐20 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 31849062

Group type: EXPERIMENTAL
Intervention: Commercial pesticide (26.7% boscalid + 6.7% pyraclostrobin) at varying concentrations
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Calibration model for boscalid
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Calibration model for pyraclostrobin
Number of subjects: 480